nofazinlimab

Nofazinlimab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor. By binding to PD-1, it blocks the interaction with its ligands PD-L1 and PD-L2, thereby enhancing T lymphocyte activity and promoting antitumor immune responses. Nofazinlimab is being developed primarily for the treatment of advanced hepatocellular carcinoma (HCC), often in combination with lenvatinib. It has demonstrated good safety and tolerability in early-phase studies, with preliminary evidence of antitumor activity across multiple solid tumor types. The drug has received Orphan Drug Designation from the U.S. FDA for HCC and is currently in Phase III clinical trials for this indication[1][2][3][4][5][6][7].

Other names

antibody cs1003recombinant pd-1 mab cs1003immunoglobulin g4 anti-(human programmed cell death protein 1) monoclonal cs1003